The primary benefit of Kadcyla is its targeted approach, which allows for effective treatment with potentially fewer side effects compared to traditional chemotherapy. By delivering the cytotoxic agent directly to the cancer cells, it reduces the collateral damage to healthy cells. Clinical trials have shown that Kadcyla can improve progression-free survival and overall survival in patients with HER2-positive breast cancer.
